Advice for Community Oncologists for Treatment Selection for Advanced RCC
July 24th 2024Matthew Campbell, MD, MS, and Rana McKay, MD, provide guidance to community oncologists on choosing between immunotherapy combination (IO/IO) and immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens for patients with advanced renal cell carcinoma.
Biomarkers: Impact on Treatment Choices and Future Expectations
July 17th 2024The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.
Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens
July 10th 2024Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.
Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
July 3rd 2024Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.
Review of CheckMate-214: Long-term follow-up in favorable risk subgroup
July 3rd 2024Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.
Current treatment options for ccRCC based on patient and disease factors
June 26th 2024Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.
Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
June 21st 2024A key opinion leader addresses the persistent challenges and unmet needs in the management of advanced urothelial carcinoma, while offering their insight into the future direction and potential advancements within this rapidly evolving field of oncology.
Managing a Novel Therapeutic Option for mUC Treatment
June 21st 2024A leading medical authority shares their hands-on experience with sacituzumab govitecan, focusing on the primary toxicity concerns, such as diarrhea and neutropenia, and outlining effective management strategies to mitigate these adverse effects and optimize patient care.
Navigating Later-Line Therapies for Progressive Urothelial Cancer
June 21st 2024A key opinion leader delves into the intricacies of second-line and third-line treatment sequencing for patients with progressive disease, addressing the appropriate timing for repeat testing and elaborating on the critical factors that inform their personalized treatment approach.
Navigating First-Line Treatment Choices for Metastatic Urothelial Carcinoma
June 21st 2024A medical professional outlines their preferred first-line treatment strategy for managing patients diagnosed with metastatic urothelial carcinoma, providing valuable insights into their clinical decision-making process.
Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
June 21st 2024A leading expert in the field shares their insights on the specific biomarkers they evaluate, such as Trop2, FGFR, and PD-L1, and the optimal timing for conducting these tests based on their clinical experience and patient management strategies.
Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
June 21st 2024A key opinion leader offers a comprehensive overview of the present landscape of molecular testing in metastatic urothelial cancer, elaborating on how advancements in molecular testing have shaped his clinical practice and expressing optimism for their future incorporation into the National Comprehensive Cancer Network (NCCN) guidelines.
Metastatic Urothelial Carcinoma: Optimizing Care Through Multidisciplinary Teamwork
June 21st 2024A urology expert elucidates the collaborative relationship between medical oncology and urology in terms of diagnostic testing, treatment strategies, and patient referrals, while underscoring the crucial role of a multidisciplinary approach in maximizing positive patient outcomes.
Emerging Treatment Options for Myelofibrosis
June 3rd 2024Dr. Bose discusses the potential role of other treatment modalities, such as ruxolitinib combination therapies or novel agents, in managing this patient's myelofibrosis and anemia, including the emerging treatment options that may be relevant to this case.